FY2025 EPS Estimates for Certara Lowered by Leerink Partnrs

Certara, Inc. (NASDAQ:CERT) – Stock analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Certara in a research report issued to clients and investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.28 per share for the year, down from their previous estimate of $0.29. The consensus estimate for Certara’s current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara’s FY2028 earnings at $0.44 EPS.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. The business had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. Certara’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 EPS.

A number of other analysts also recently weighed in on CERT. Robert W. Baird increased their price target on shares of Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a report on Friday, April 11th. Barclays raised shares of Certara from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $11.00 to $14.00 in a report on Thursday, May 8th. JMP Securities reissued a “market perform” rating on shares of Certara in a report on Tuesday, May 6th. KeyCorp increased their price target on shares of Certara from $15.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, April 16th. Finally, Morgan Stanley initiated coverage on shares of Certara in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 price target for the company. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.71.

Certara Price Performance

NASDAQ CERT opened at $11.09 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27. The company has a fifty day simple moving average of $11.42 and a 200 day simple moving average of $11.86. The company has a market cap of $1.80 billion, a P/E ratio of -554.50 and a beta of 1.43. Certara has a 1 year low of $8.64 and a 1 year high of $16.93.

Hedge Funds Weigh In On Certara

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Harbor Capital Advisors Inc. lifted its holdings in shares of Certara by 41.3% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 28,670 shares of the company’s stock worth $335,000 after acquiring an additional 8,376 shares during the period. Jane Street Group LLC lifted its holdings in shares of Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after acquiring an additional 40,463 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after acquiring an additional 35,954 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Certara by 65.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after acquiring an additional 90,724 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Certara during the 1st quarter worth about $297,000. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.